2. Academic Validation
  3. Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)

Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)

  • Sci Rep. 2015 Dec 1;5:17391. doi: 10.1038/srep17391.
Kim Huard 1,  Janice Brown 2,  Jessica C Jones 3,  Shawn Cabral 4,  Kentaro Futatsugi 1,  Matthew Gorgoglione 3,  Adhiraj Lanba 3,  Nicholas B Vera 3,  Yimin Zhu 3,  Qingyun Yan 3,  Yingjiang Zhou 3,  Cecile Vernochet 3,  Keith Riccardi 2,  Angela Wolford 2,  David Pirman 2,  Mark Niosi 2,  Gary Aspnes 1,  Michael Herr 4,  Nathan E Genung 4,  Thomas V Magee 1,  Daniel P Uccello 4,  Paula Loria 2,  Li Di 2,  James R Gosset 5,  David Hepworth 1,  Timothy Rolph 3,  Jeffrey A Pfefferkorn 3,  Derek M Erion 3
Affiliations

Affiliations

  • 1 Worldwide Medicinal Chemistry, 610 Main street, Cambridge, MA 02139.
  • 2 Pharmacokinetics, Dynamics, and Metabolism, Eastern Point road, Groton, CT 06340.
  • 3 Cardiovascular, Metabolic &Endocrine Disease Research Unit, 610 Main street, Cambridge, MA 02139.
  • 4 Worldwide Medicinal Chemistry, Eastern Point road, Groton, CT 06340.
  • 5 Pharmacokinetics, Dynamics, and Metabolism, 610 Main street, Cambridge, MA 02139.
PMID: 26620127 DOI: 10.1038/srep17391
Abstract

Citrate is a key regulatory metabolic intermediate as it facilitates the integration of the glycolysis and lipid synthesis pathways. Inhibition of hepatic extracellular citrate uptake, by blocking the sodium-coupled citrate transporter (NaCT or SLC13A5), has been suggested as a potential therapeutic approach to treat metabolic disorders. NaCT transports citrate from the blood into the cell coupled to the transport of sodium ions. The studies herein report the identification and characterization of a novel small dicarboxylate molecule (compound 2) capable of selectively and potently inhibiting citrate transport through NaCT, both in vitro and in vivo. Binding and transport experiments indicate that 2 specifically binds NaCT in a competitive and stereosensitive manner, and is recognized as a substrate for transport by NaCT. The favorable pharmacokinetic properties of 2 permitted in vivo experiments to evaluate the effect of inhibiting hepatic citrate uptake on metabolic endpoints.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z